Phencyclidine (PCP) is a dissociative anesthetic that is a commonly used recreational drug. PCP is a crystalline powder that can be ingested orally, injected intravenously, inhaled, or smoked. After being discovered in 1926, PCP was developed as a general anesthetic in the 1950s because it could achieve analgesia and anesthesia with minimal cardiovascular and respiratory suppression. It was marketed under the name Sernyl. In 1963, Sernyl began to be used in surgical procedures. By 1967, it was discontinued due to postoperative dysphoria and hallucinations. After 1967, it was limited to veterinary use. Also in the 1960s, PCP began to be illegally manufactured in laboratories and emerged as a popular street drug in San Francisco. In the 1970s, PCP use became widespread. Common street names for PCP are the peace pill, angel dust, crystal joints, rocket fuel, sawgrass, zoom, the sheets and elephant tranquilizer. Depending on the dose and route of administration, PCP can have a wide range of central nervous system (CNS) manifestations. Emergency department providers should become familiar with how to manage patients with PCP toxicity since rhabdomyolysis, hypoglycemia, seizures, hypertensive crisis, coma, and trauma are several of the complications that can arise with PCP use.
There were 75,538 emergency department visits in 2011 due to PCP, according to the Drug Abuse Warning Network. This was up 400% from 2005 (14,825). Seventy-two percent of PCP-related emergency department visits in 2011 involved PCP used in combination with other drugs such as marijuana, cocaine, analgesics, and anxiolytics. The majority of emergency department visits due to PCP in 2011 involved male patients (69%). Forty-five percent were patients who were 25 to 34 years old. Patients who were aged 18 to 24 years old and 35 to 44 years old accounted for 19% of emergency department visits each. According to the American Association of Poison Control Centers, there were two deaths from PCP in 2012.
PCP is available as a powder, crystal, liquid, and tablet. It produces both stimulation and depression of the CNS. PCP is a noncompetitive antagonist to the NMDA receptor, which causes analgesia, anesthesia, cognitive defects, and psychosis. PCP blocks the uptake of dopamine and norepinephrine, leading to sympathomimetic effects such as hypertension, tachycardia, bronchodilation, and agitation. PCP can also cause sedation, muscarinic, and nicotinic signs by binding to acetylcholine receptors and GABA receptors. Sigma receptor stimulation by PCP causes lethargy and coma.
PCP, also known as 1-(1-phenylcyclohexyl-piperidine), is a synthetic arycycloalkylamine created from piperidine and cyclohexanone. It has a volume distribution of 6.2 L/kg and a pH between 8.6 and 9.4. It is soluble in water and ethanol. PCP begins to cause symptoms at a dose of 0.05mg/kg, and a dose of 20 mg or more can cause seizures, coma, and death. It is mainly metabolized by the liver, and 10% is excreted in the kidneys. Inhalation (the most common route of administration) and intravenous routes of administration produce symptoms in 2 to 5 minutes. Oral ingestion produces symptoms in 30 to 60 minutes. The half-life is estimated to be 21 hours, but symptoms can last from several hours up to 48 hours, depending on the dose. Recurrent, fluctuating symptoms can occur because PCP is fat-soluble and can be released from lipid stores and adipose tissue that can occur days to months after the initial use.
Depending on the dose, administration route, and coingestants, PCP can cause a wide spectrum of clinical effects, from coma to extreme agitation or psychosis. Many times, patients are unable to give a clear history, so it is imperative to attempt to obtain a history from emergency medical personnel, family, friends, and witnesses. Familiarity with the street names for PCP can be helpful as well.
The evaluation should include the following:
Most patients survive PCP intoxication with supportive care. Airway, breathing, circulation, and hemodynamic monitoring are essential to the care of patients with PCP toxicity. Intubation with ventilatory support may be required for airway protection.
Gastrointestinal decontamination is generally unnecessary in PCP ingestions; however, activated charcoal may be beneficial with a massive ingestion of PCP or a dangerous coingestion. Activated charcoal therapy should only be started within one hour from the time of ingestion. The activated charcoal dose is 1 g/kg, with a maximum dose of 50 g.
Sedation with medication and physical restraints may be required to control agitation, violent behavior, and psychosis due to PCP intoxication. Placing the patient in a calm environment such as a quiet room with the lights dimmed may be helpful. Benzodiazepines are the preferred medication for chemical sedation in patients with PCP toxicity. Lorazepam 2 to 4 mg intravenous (IV) or intramuscular (IM), or diazepam 5 to 10 mg IV or IM are recommended. Repeated doses every 10 minutes may be required for adequate sedation. Benzodiazepines are also the first-line treatment for PCP-induced hypertension and seizures. Hyperthermia from PCP toxicity is due to psychomotor agitation and can be successfully treated with benzodiazepines as well.
Patients with mild symptoms can be discharged one to 2 hours after they become symptom-free and have no other medical complications or behavioral issues that need to be addressed. Patients with severe symptoms or medical complications should be admitted to a monitored bed. Patients who are asymptomatic who present to the emergency department after PCP use should be observed for at least 6 hours before being discharged. Psychiatric evaluation should be considered in patients whose medical symptoms/complications have resolved but required further management of behavioral issues.
PCP toxicity is best managed by an interprofessional team that also includes ER and ICU nurses. The majority of patients require supportive treatment with close monitoring of hemodynamics. In mild cases, recovery is possible within6-12 hours. Severe cases may require admission to the ICU. Prior to discharge, a mental health nurse consult may be required to determine if this was accidental or an intentional overdose.
|||Wallach J,Brandt SD, 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances. Handbook of experimental pharmacology. 2018 Sep 9; [PubMed PMID: 30196446]|
|||Grayson B,Barnes SA,Markou A,Piercy C,Podda G,Neill JC, Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review. Current topics in behavioral neurosciences. 2016; [PubMed PMID: 26510740]|
|||Misselbrook GP,Hamilton EJ, Out with the old, in with the new? Case reports of the clinical features and acute management of two novel designer drugs. Acute medicine. 2012; [PubMed PMID: 22993747]|
|||Meltzer HY,Horiguchi M,Massey BW, The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology. 2011 Feb; [PubMed PMID: 21212939]|
|||Koseki T,Nabeshima T, [Phencyclidine abuse, dependence, intoxication, and psychosis]. Nihon rinsho. Japanese journal of clinical medicine. 2010 Aug; [PubMed PMID: 20715485]|
|||Schwartz RH, Adolescent abuse of dextromethorphan. Clinical pediatrics. 2005 Sep; [PubMed PMID: 16151560]|
|||Morris BJ,Cochran SM,Pratt JA, PCP: from pharmacology to modelling schizophrenia. Current opinion in pharmacology. 2005 Feb; [PubMed PMID: 15661633]|